<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">DREHER, TOBIAS C.</style></author><author><style face="normal" font="default" size="100%">EL-BATTRAWY, IBRAHIM</style></author><author><style face="normal" font="default" size="100%">RÖGER, SUSANNE</style></author><author><style face="normal" font="default" size="100%">ROSENKAIMER, STEPHANIE L.</style></author><author><style face="normal" font="default" size="100%">GERHARDS, STEFAN</style></author><author><style face="normal" font="default" size="100%">KUSCHYK, JÜRGEN</style></author><author><style face="normal" font="default" size="100%">BORGGREFE, MARTIN</style></author><author><style face="normal" font="default" size="100%">AKIN, IBRAHIM</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for &amp;lt;90 Wear Days &lt;em&gt;versus&lt;/em&gt; ≥90 Wear Days</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3601-3610</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12205</style></doi><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The wearable cardioverter/defibrillator (WCD) is recommended to prevent sudden cardiac death (SCD). Guidelines suggest a 90 days' period, but prolongation of WCD wear time until increasing the ejection fraction (≥35%) might be suggested. Patients and Methods: A cohort of 153 patients with prescribed WCD were divided into two groups: A &lt;90 wear days' group (n=112) vs. ≥90 wear days' group (n=41) and followed. Results: In the first group, WCD shock occurred in 3.6% of patients, 47.3% improved in left ventricular ejection fraction (LVEF) after 3 months, and 37.5% had a cardiac implantable electronic device (CIED) implantation with appropriate implantable cardioverter defibrillator (ICD) shock events occurring in 6 patients. Two of these patients already received WCD shock therapy due to ventricular fibrillation. A 20.5% improved in LVEF after 6-12 months, but 73% were already implanted with ICD. In the second group, 4.9% received WCD shock, 34.1% improved in LVEF after 3 months, 48.8% were implanted with ICD, and 2 had ICD shocks during follow up time. LVEF improvement after 6-12 months occurred in 26.8%. ICD implantation was prevented in 7.3% of patients due to LVEF recovery. Conclusion: Prolonging wearing days of WCD may reduce the number of inappropriate ICD implantation.</style></abstract></record></records></xml>